Corporate venture firms are a well-established presence on the biotech funding scene, with the likes of Novartis and Glaxosmithkine’s SR One among the most active investors in the sector. However, the past few years have seen some different names crop up more and more: Pfizer, Celgene and Roche have noticeably stepped up their financing activity, a new analysis by EP Vantage finds.
BioMarker Strategies, LLC, today announced that the Japan Patent Office has granted new patents covering the Company’s SnapPath® Cancer Diagnostics System technology and its PathMAP® Functional Signaling Profile technology.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices
Requests for Applications
Program Announcements
The MOVE program is an innovative approach intended to attract new businesses to Montgomery County, Maryland. Eligible new businesses will receive a one-time grant upon signing a commercial lease within the county.
Businesses new to the county that lease up to 20,000 square feet of Class A or B office space may receive a grant of $8/sf. All grants are capped at 10,000 square feet for purposes of calculating the grant award.
The university and life science giants AstraZeneca and MedImmune have joined forces with the burgeoning Cambridge Biomedical Campus and pledged to work with the Government and partners in areas identified as major catalysts for growth.
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to accurately identify more than half of 138 people with relatively early-stage colorectal, breast, lung and ovarian cancers. The test, the scientists say, is novel in that it can distinguish between DNA shed from tumors and other altered DNA that can be mistaken for cancer biomarkers.
BrainScope Company, Inc., the medical neurotechnology company which created the first FDA-cleared handheld medical device for assessment of the full spectrum of traumatic brain injury, today announced it has completed a $16 million equity financing. New investor DBL Partners joined previous backers Revolution LLC, ZG Ventures, Maryland Venture Fund and other existing and new investors in the round, which the company will use to support the commercial launch of its flagship BrainScope One medical device, as well as for continued research and development initiatives.
Tue, Sep 19, 2017 at 7:30 AM – American Visionary Art Museum800 Key HighwayJRVC 3rd FloorBaltimore, MD 21230
Already dubbed a ‘tech hub’, the Baltimore-Washington region has built a solid foundation in cyber activities as they pertain to government agencies and defense contracting. Now a transformation is underway to build up the commercial side of cyber. And that’s precisely what this panel will reinforce.
AstraZeneca has sold off marketing and development rights to another one of its pipeline assets.
This time it’s Takeda that’s stepping up, inking a deal package totaling $400 million for development and commercialization rights to its home grown MEDI1341, an alpha-synuclein antibody designed to combat Parkinson’s disease.
Virginia Bio, the premier statewide non-profit association of the life science industry in Virginia, elected Andrew J. Krouse to a two-year term as Chairman of the Board of Directors, during the annual meeting of the Board held at i.Lab at UVA.
